Work

Enhancing the Stability of 211At Radiopharmaceuticals: Insights from Ortho-Substituent Strategies

Year: 2025

Type: editorial

Abstract: High Resolution Image Download MS PowerPoint Slide Astatine-211 ( 211 At) is a promising alpha-emitting radionuclide for targeted alpha therapy (TAT), delivering high linear energy transfer (LET) and a short radiation range, making it ideal for cancer treatment while minimizing damage to surrounding healthy tissue. This viewpoint highlights recent advancements in the development of astatine-211 compounds for TAT, with a focus on the role of neighboring substituents in enhancing in vivo stability. By mitigating deastatination, these structural modifications improve radiopharmaceutical integrity, paving the way for more effective and clinically viable 211 At-based radiopharmaceuticals.

Source: ACS Medicinal Chemistry Letters

DOI: 10.1021/acsmedchemlett.5c00102

Authors: Taoqian Zhao, Steven H. Liang

Institution: Emory University

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,500